Comparing Zymeworks (NASDAQ:ZYME) & Reliv’ International (OTCMKTS:RELV)

Reliv’ International (OTCMKTS:RELV) and Zymeworks (NASDAQ:ZYME) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Insider and Institutional Ownership

7.8% of Reliv’ International shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 30.0% of Reliv’ International shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Reliv’ International has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Reliv’ International and Zymeworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reliv’ International	-0.61%	-1.89%	-1.31%
Zymeworks	-126.92%	-37.97%	-25.31%

Earnings & Valuation

This table compares Reliv’ International and Zymeworks”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv’ International	$35.06 million	0.10	-$440,000.00	($0.09)	-22.22
Zymeworks	$105.96 million	16.46	-$81.13 million	($1.37)	-17.44

Reliv’ International has higher earnings, but lower revenue than Zymeworks. Reliv’ International is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Reliv’ International and Zymeworks, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv’ International	0	0	0	0	0.00
Zymeworks	1	1	9	2	2.92

Zymeworks has a consensus price target of $38.00, indicating a potential upside of 59.07%. Given Zymeworks’ stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than Reliv’ International.

Summary

Zymeworks beats Reliv’ International on 10 of the 15 factors compared between the two stocks.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.